Since PTP1B and PTPN2 can function as intracellular checkpoints to tune T cell responses7,11,14, one possible adverse consequence of systemically targeting PTP1B and PTPN2 with small molecule inhibitors may be the development of CRS and autoimmunity. Here, PTPN1 is linked to Autoimmunity.